-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

Benzinga·01/21/2026 14:38:20
Listen to the news
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $22 to $13.